Salarius Pharmaceuticals Inc expected to post a loss of $2.59 a share - Earnings Preview

Decoy Therapeutics

08/05/2023 14:05

* Salarius Pharmaceuticals Inc  SLRX.OQ   SLRX.O  is
expected
to show no change in quarterly revenue when it reports 
results on May 10 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Salarius
Pharmaceuticals
Inc is for a loss of $2.59 per share. 
    * The one available analyst rating on the shares is "strong
buy".  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Salarius
Pharmaceuticals Inc is $70.5​, above​ its last closing price
of $1.83. ​​​

This summary was machine generated May 8 at 13:05 GMT.  All
figures in US dollars  unless otherwise stated